Antibody-drug nanocell conjugates (EnGeneIC)

N/A

Report date: 2025/06/05 20:00:13

Base Information

Drug NameAntibody-drug nanocell conjugates (EnGeneIC)
Drug Alias NameEGFR-EDV-RRM1EGFR-EDV-PLKEGFR-EDV-Dox
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEngeneic Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEngeneic Pty Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A